IMDX · Insight Molecular Diagnostics Inc. · Financials
The latest filing states the doubt was alleviated.
“Our expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that the consolidated financial statements are issued. ... Management has concluded that it is probable that our plans will be effectively implemented and that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about our ability to continue as a going concern within one year after the date of issuance of these consolidated financial statements. ... Accordingly, management has concluded that substantial doubt does not exist about the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements.”View the 10-Q filed Aug 10, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.67M | $4.06M | $1.88M | $1.5M | $958K | $2.2M | $1.22M | — | — | — | — | $0 | — | |
| -$98K | -$109K | -$84K | -$52K | -$83K | -$209K | -$252K | $299K | -$216K | -$217K | -$28K | -$19K | -$2000 | |
| $856K | $1.75M | $1.05M | $1M | $880K | $697K | $1.86M | — | — | — | — | — | — | |
| $807K | $2.3M | $740K | $413K | -$18K | $1.42M | -$639K | — | — | — | — | — | — | |
| — | 56.67% | 39.34% | 27.48% | -1.88% | 64.6% | -52.55% | — | — | — | — | — | — | |
| $19.15M | $15.9M | $9.84M | $9.29M | $7.3M | $5.04M | $9.8M | $6.79M | $6.51M | $7.17M | $5.68M | $4.53M | $3.96M | |
| $8M | $6.34M | $3.94M | $2.8M | $1.13M | $552K | $6.49M | $2.16M | $1.68M | $2.44M | $1.2M | $324K | — | |
| $10.74M | $10.63M | $10.2M | $11.18M | $21.88M | $22.29M | $16.79M | $13.28M | $7.01M | $9.23M | $4.27M | $3.87M | $1.01M | |
| $0 | $7000 | $88K | $88K | $3.69M | $3.36M | $81K | — | $121K | $242K | $242K | $242K | $242K | |
| $2.44M | $2.2M | $1.56M | $1.68M | $1.53M | $800K | $313K | — | — | — | — | — | — | |
| $51.11M | $53.42M | $61.78M | $25.55M | $17.98M | $55.15M | $29.07M | $22.24M | $15.2M | $18.85M | $11.14M | $8.72M | $4.97M | |
| -$50.3M | -$51.12M | -$61.04M | -$25.14M | -$18M | -$53.73M | -$29.71M | -$22.24M | -$15.2M | -$18.85M | -$11.14M | -$8.72M | -$4.97M | |
| — | -1260.76% | -3245.14% | -1672.39% | -1878.6% | -2444.27% | -2443.34% | — | — | — | — | — | — | |
| -$47.86M | -$48.93M | -$59.48M | -$23.46M | -$16.47M | -$52.93M | -$29.4M | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | $0 | $18K | $0 | |
| $939K | $902K | $378K | $281K | -$615K | $854K | -$1.48M | -$187K | -$552K | -$526K | -$28K | -$17K | -$13K | |
| — | — | — | — | — | -$270K | -$1.55M | -$281K | — | — | — | — | — | |
| — | — | -$60.66M | -$24.86M | -$18.61M | -$52.87M | -$31.19M | -$22.43M | — | — | — | — | — | |
| $0 | $0 | $0 | $0 | — | -$9.26M | -$1.25M | — | — | — | — | — | — | |
| -$49.36M | -$50.22M | -$60.66M | -$27.78M | -$72.9M | -$64.1M | -$29.93M | -$22.43M | -$15.75M | -$19.38M | -$11.17M | -$8.74M | -$4.99M | |
| — | -1238.52% | -3225.04% | -1848.37% | -7609.81% | -2916.15% | -2461.51% | — | — | — | — | — | — | |
| — | -$50.22M | -$60.93M | -$28.72M | -$73.42M | -$64.1M | — | — | — | — | — | — | — | |
| -$49.38M | -$50.16M | -$60.69M | -$27.77M | -$72.9M | -$64.06M | -$29.93M | -$22.43M | -$15.75M | -$19.61M | -$11.47M | -$8.26M | -$4.44M | |
| USD/shares | -$1.52 | -$1.65 | -$4.66 | -$3.75 | -$13.25 | -$14.40 | — | — | — | — | — | — | — |
| USD/shares | -$1.52 | -$1.65 | -$4.66 | -$3.75 | -$13.25 | — | — | — | — | — | — | — | — |
| shares | — | 30.48M | 13.07M | 7.65M | 5.54M | 4446 | 3273.9 | 2.56M | 1.89M | 1.51M | 1.33M | 1.05M | 910K |
| shares | — | 30.48M | 13.07M | 7.65M | 5.54M | 4446 | 3273.9 | 2.56M | 1.89M | 1.51M | 1.33M | 1.05M | 910K |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Finance lease liabilities | 2026-06-30 | USD 766,000 | 10-Q filed 2026-08-10 |
| Operating lease liabilities | 2026-06-30 | USD 1,679,000 | 10-Q filed 2026-08-10 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 11 similar-size Diagnostics & Research companies (of 50 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| United States | $4,031,000 | $1,673,000 | $923,000 |
| Europe | $24,000 | $18,000 | — |
| United Kingdom | $0 | $45,000 | $409,000 |
| Asia Pacific | $0 | $145,000 | $160,000 |
| Spain | — | — | $11,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Laboratory Services | $4,031,000 | $1,859,000 | — |
| Kitted Products | $24,000 | $0 | — |
| Laboratory Developed Test Services | $0 | $22,000 | — |
| Laboratory Developed Test Services | — | — | $36,000 |
| Pharma Services | — | — | $1,467,000 |